Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subject

British Journal of Clinical Pharmacology

Volumn 59, Issue 4, 2005, Pages 405-414

  Astruc, Béatrice ^a   Tarral, Antoine ^a   Dostert, Philippe ^a   Mariotti, Fabrizia ^b   Fabbri, Laura ^b   Imbimbo, Bruno P ^b  

^a Biotrial SA   (France)

^b Research and Development Department   (Italy)

Author keywords

CHF3381; MAO A inhibitors; Neuropathic pain; NMDA antagonists

Indexed keywords

2 AMINOINDAN; 3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; ALANINE AMINOTRANSFERASE; CHF 3381; CHF 3567; DRUG METABOLITE; INDAN DERIVATIVE; MANDELIC ACID; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALERTNESS; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; ATTENTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ENZYME ACTIVITY; HEART RATE; HUMAN; HUMAN EXPERIMENT; INFORMATION PROCESSING; INSOMNIA; MALE; MEMORY; MOTOR COORDINATION; NEUROPATHIC PAIN; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SYNCOPE; VISUAL ANALOG SCALE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANALGESICS; AREA UNDER CURVE; ATTENTION; CENTRAL NERVOUS SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; GLYCINE; HALF-LIFE; HUMANS; INDANS; MALE; MEMORY; PAIN; PSYCHOMOTOR PERFORMANCE;

EID: 17144371302     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02338.x     Document Type: Article

References (38)

1. McCleane G. Pharmacological management of neuropathic pain. CNS Drugs 2003; 17: 1031-43.
2. Woolf CJ, American College of Physicians, American Physiological Society. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 2004; 140: 441-51.
3. Eide K, Stubhaug A, Oye I, Breivik H. Continuous subcutaneous administration of the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia. Pain 1995; 61: 221-8.
4. Carlsson KC, Hoem NO, Moberg ER, Mathisen LC. Analgesic effect of dextromethorphan in neuropathic pain. Acta Anaesthesiol Scand 2004; 48: 328-36.
5. Schreiber S, Getslev V, Weizman A, Pick CG. The antinociceptive effect of moclobemide in mice is mediated by noradrenergic pathways. Neurosci Lett 1998; 253: 183-6.
6. Coquoz D, Porchet HC, Dayer P. Central analgesic effects of desipramine, fluvoxamine, and moclobemide after single oral dosing: a study in healthy volunteers. Clin Pharmacol Ther 1993; 54: 339-44.
7. Pirildar S, Sezgin U, Elbi H, Uyar M, Zileli B. A preliminary open-label study of moclobemide treatment of pain disorder. Psychopharmacol Bull 2003; 37: 127-34.
8. CHF 3381. Drugs RD 2004; 5: 28-30.
9. Barbieri M, Bregola G, Buzzi A, Marino S, Zucchini S, Stables JP, Bergamaschi M, Pietra C, Villetti G, Simonato M. Mechanisms of action of CHF3381 in the forebrain. Br J Pharmacol 2003; 139: 1333-41.
10. Gandolfi O, Bonfante V, Voltattorni M, Dall'Olio R, Poli A, Pietra C, Villetti G. Anticonvulsant preclinical profile of CHF 3381: dopaminergic and glutamatergic mechanisms. Pharmacol Biochem Behav 2001; 70: 157-66.
11. Zucchini S, Buzzi A, Bergamaschi M, Pietra C, Villetti G, Simonato M. Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate antagonist. Neuroreport 2002; 13: 2071-4.
12. Villetti G, Bregola G, Bassani F, Bergamaschi M, Rondelli I, Pietra C, Simonato M. Preclinical evaluation of CHF3381 as a novel antiepileptic agent. Neuropharmacology 2001; 40: 866-78.
13. Villetti G, Bergamaschi M, Bassani F, Bolzoni PT, Maiorino M, Pietra C, Rondelli I, Chamiot-Clerc P, Simonato M, Barbieri M. Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 2003; 306: 804-14.
14. Tarral A, Dostert P, Guillevic Y, Fabbri L, Rondelli I, Mariotti F, Imbimbo BP. Safety, pharmacokinetics and pharmacodynamics of CHF3381, a novel NMDA antagonist, after single oral doses in healthy subjects. J Clin Pharmacol 2003; 43: 901-11.
15. Coull JT, Frith CD, Frackowiak RS, Grasby PM. A fronto-parietal network for rapid visual information processing: a PET study of sustained attention and working memory. Neuropsychologia 1996; 34: 1085-95.
16. Patat A. Clinical pharmacology of psychotropic drugs. Hum Psychopharmacol 2000; 15: 361-87.
17. Bond AJ, Lader MH. The use of analogue scales in rating subjective feeling. Br J Clin Psychol 1974; 47: 211-8.
18. McClelland GR. Body sway and the effects of psychoactive drugs: a review. Human Psychopharmacol 1989; 4: 3-14.
19. Patat A, le Coz F, Dubruc C, Gandon JM, Durrieu G, Cimarosti I, Jezequel S, Curet O, Zieleniuk I, Allain H, Rosenzweig P. Pharmacodynamics and pharmacokinetics of two dose regimens of befloxatone, a new reversible and selective monoamine oxidase inhibitor, at steady state in healthy volunteers. J Clin Pharmacol 1996; 36: 216-29.
20. Gottrup H, Bach FW, Arendt-Nielsen L, Jensen TS. Peripheral lidocaine but not ketamine inhibits capsaicin-induced hyperalgesia in humans. Br J Anaesth 2000; 85: 520-8.
21. Heiskanen T, Hartel B, Dahl ML, Seppala T, Kalso E. Analgesic effects of dextromethorphan and morphine in patients with chronic pain. Pain 2002; 96: 261-7.
22. Wilcock G, Mobius HJ, Stoffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM 500). Int Clin Psychopharmacol 2002; 17: 297-305.
23. Jarvis B, Figgitt DP. Memantine. Drugs Aging 2003; 20: 465-76.
24. Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS Drug Rev 2003; 9: 97-140.
25. Lott M, Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Katz RJ, Schaettle SC. Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study. J Clin Psychopharmacol 1997; 17: 255-60.
26. Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995; 26: 503-13.
27. Stefansson T, Wickstrom I, Haljamae H. Hemodynamic and metabolic effects of ketamine anesthesia in the geriatric patient. Acta Anaesthesiol Scand 1982; 26: 371-7.
28. Albers GW, Atkinson R, Kelley R, Rosenbaum DM. Safety, tolerability, and pharmacokinetics of the N-methyl D-aspartate antagonist dextrorphan in patients with an acute stroke. Neurology 1994; 44(Suppl 2): A270-1.
29. Fisher K, Coderre TJ, Hagen NA. Targeting the N-methyl-D-aspartate receptor for chronic pain management. Preclinical animal studies, recent clinical experience and future research directions. J Pain Symptom Manage 2000; 20: 358-73.
30. Farber NB. The NMDA receptor hypofunction model of psychosis. Ann N Y Acad Sci 2003; 1003: 119-30.
31. Mrongovius RI, Bolt AG, Hellyer RO. Comparison of the anorectic and motor activity effects of some aminoindanes, 2-aminotetralin and amphetamine in the rat. Clin Exp Pharmacol Physiol 1978; 5: 635-40.
32. Dingemanse J, Kneer J, Wallnofer A, Kettler R, Zurcher G, Koulu M, Korn A. Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline. Clin Neuropharmacol 1996; 19: 399-414.
33. Bitsios P, Langley RW, Tavernor S, Pyykko K, Scheinin M, Szabadi E, Bradshaw CM. Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man. Br J Clin Pharmacol 1998; 45: 551-8.
34. Scheinin M, Illi A, Koulu M, Ojala-Karlsson P. Norepinephrine metabolites in plasma as indicators of pharmacological inhibition of monoamine oxidase and catechol O-methyltransferase. Adv Pharmacol 1998; 42: 367-70.
35. Dennis T, Benkelfat C, Touitou Y, Auzeby A, Poirier MF, Scatton B, Loo H. Lack of circadian rhythm in plasma concentrations of 3,4- dihydroxyphenylethyleneglycol in healthy human subjects. Psychopharmacology 1986; 90: 471-4.
36. Holford NH, Guentert TW, Dingemanse J, Banken L. Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor. Br J Clin Pharmacol 1994; 37: 433-9.
37. Gleiter CH, Muhlbauer B, Schulz RM, Nilsson E, Antonin KH, Bieck PR. Monoamine oxidase inhibition by the MAO-A inhibitors brofaromine and clorgyline in healthy volunteers. J Neural Transm General Sect 1994; 95: 241-5.
38. Berlin I, Zimmer R, Thiede HM, Payan C, Hergueta T, Robin L, Puech AJ. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. Br J Clin Pharmacol 1990; 30: 805-16.